Avicenna Biosciences is a biotechnology company that develops drug candidates using advanced technologies. Established in 2020, the company specializes in using machine-learning-enhanced medicinal chemistry to accelerate the optimization process from lead compounds to viable drug candidates. This approach is designed to streamline the lead-to-candidate optimization process for small-molecule drug development. As of February 2024, the company was focused on developing AVI-016, a treatment for amyotrophic lateral sclerosis, a progressive neurodegenerative disease.
Funding and financials
In February 2024, Avicenna Biosciences raised USD 6 million in debt financing . The funds were allocated to fuel the company’s ongoing drug discovery and development process to treat neurodegenerative diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.